Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

In vitro comparative models for canine and human breast cancers.

Visan S, Balacescu O, Berindan-Neagoe I, Catoi C.

Clujul Med. 2016;89(1):38-49. doi: 10.15386/cjmed-519. Epub 2016 Jan 15. Review.

2.

Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression.

Suárez-Arroyo IJ, Rios-Fuller TJ, Feliz-Mosquea YR, Lacourt-Ventura M, Leal-Alviarez DJ, Maldonado-Martinez G, Cubano LA, Martínez-Montemayor MM.

J Cancer. 2016 Feb 5;7(5):500-11. doi: 10.7150/jca.13599. eCollection 2016.

3.

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.

Denu RA, Hampton JM, Currey A, Anderson RT, Cress RD, Fleming ST, Lipscomb J, Sabatino SA, Wu XC, Wilson JF, Trentham-Dietz A.

Cancer Epidemiol. 2016 Feb;40:7-14. doi: 10.1016/j.canep.2015.11.003. Epub 2015 Nov 21.

PMID:
26605428
4.

A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.

Wurth R, Tarn K, Jernigan D, Fernandez SV, Cristofanilli M, Fatatis A, Meucci O.

Transl Oncol. 2015 Oct;8(5):358-67. doi: 10.1016/j.tranon.2015.07.002.

5.
6.

Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening.

Theodoraki MA, Rezende CO Jr, Chantarasriwong O, Corben AD, Theodorakis EA, Alpaugh ML.

Oncotarget. 2015 Aug 28;6(25):21255-67.

7.

Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366.

Caceres S, Peña L, de Andres PJ, Illera MJ, Lopez MS, Woodward WA, Reuben JM, Illera JC.

PLoS One. 2015 Mar 25;10(3):e0122277. doi: 10.1371/journal.pone.0122277. eCollection 2015.

8.

Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM.

Breast Cancer Res. 2015 Jan 9;17:2. doi: 10.1186/s13058-014-0507-6.

9.

Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration.

Buchheit CL, Angarola BL, Steiner A, Weigel KJ, Schafer ZT.

Cell Death Differ. 2015 Aug;22(8):1275-86. doi: 10.1038/cdd.2014.209. Epub 2014 Dec 19.

PMID:
25526094
10.

High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.

Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM.

PLoS One. 2014 Jan 8;9(1):e83113. doi: 10.1371/journal.pone.0083113. eCollection 2014.

11.

Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M.

Int J Biochem Cell Biol. 2014 Jan;46:138-47. doi: 10.1016/j.biocel.2013.11.015. Epub 2013 Nov 26.

12.

Does secondary inflammatory breast cancer represent post-surgical metastatic disease?

Hashmi S, Zolfaghari L, Levine PH.

Cancers (Basel). 2012 Feb 20;4(1):156-64. doi: 10.3390/cancers4010156.

13.

Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.

Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE.

PLoS One. 2013 Sep 11;8(9):e73464. doi: 10.1371/journal.pone.0073464. eCollection 2013.

14.

Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR.

Cancer Lett. 2013 Aug 28;337(1):77-89. doi: 10.1016/j.canlet.2013.05.017. Epub 2013 May 17.

15.

A comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells.

Martin BJ, van Golen KL.

Int J Breast Cancer. 2012;2012:412581. doi: 10.1155/2012/412581. Epub 2012 Dec 31.

16.

Diverse presentations of carcinoma erysipelatoides from a teaching hospital in australia.

Chow HT, Tran K, Millar EK, Lynch J, Murrell DF.

Case Rep Dermatol Med. 2012;2012:134938. doi: 10.1155/2012/134938. Epub 2012 Dec 23.

17.

Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway.

Ohshiro K, Bui-Nguyen TM, Divijendra Natha RS, Schwartz AM, Levine P, Kumar R.

Int J Biol Markers. 2012 Dec 27;27(4):e305-13. doi: 10.5301/JBM.2012.10437.

18.

BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.

Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, Daneshmand M, Hanson J, Nabavi M, Parolin D, Mallick R, Verma S.

Oncol Lett. 2012 Jul;4(1):141-145. Epub 2012 Apr 26.

19.

Inflammatory breast cancer: is it really a separate entity?

Bastawisy A, Gaafar R, Eisa S, Amira G, Helal M.

Ecancermedicalscience. 2012;6:250. doi: 10.3332/ecancer.2012.250. Epub 2012 Apr 12.

20.

Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling.

Ohshiro K, Schwartz AM, Levine PH, Kumar R.

PLoS One. 2012;7(1):e30725. doi: 10.1371/journal.pone.0030725. Epub 2012 Jan 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk